Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ruxolitinib in Patients Who Can’t Take Hydroxyurea

Blood; 2017 Oct 12; Verstovsek, Passamonti, et al

Patients with essential thrombocythemia (ET) who do not respond to or cannot tolerate hydroxyurea can benefit from ruxolitinib treatment, according to a small open-label phase 2 study involving 39 individuals. Participants received a median dose of 30 mg/day of ruxolitinib. Among the results:

  • Treatment with a starting dose of 25 mg twice daily was linked with improved symptoms.
  • 47% of patients experienced a ≥50% improvement in bone pain at week 12.
  • Pruritus improved in 50%, night sweats in 75%, numbness/tingling in the fingers/toes in 65%, and weakness in 35%.
  • At baseline, 62% of patients were positive for the JAK2V617F mutation.
  • Minimal decrease from baseline in JAK2V617F allele burden was seen after 24 weeks of treatment.
  • Allele burden was reduced with longer exposure.
  • The most common nonhematologic adverse events during the first 8 weeks were weight increase, cough, diarrhea, and pyrexia.
  • The most common hematologic abnormalities were anemia and leukopenia.


Verstovsek S, Passamonti F, Rambaldi A, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: Long-term phase 2 study results. Blood. 2017;130(15):1768-1771. doi:10.1182/blood-2017-02-765032.

This Week's Must Reads

Efficacy of Glecaprevir-Pibrentasvir in HCV, N Engl J Med; 2018 Jan 25; Zeuzem, et al

Cigarette Smoking in Persons Living with HCV, Am J Med; ePub 2018 Feb 3; Kim, et al

Expanded Age-Based HCV Testing in US , Clin Infect Dis; ePub 2018 Feb 6; Barocas, et al

HCV Treatment as Prevention in PWIDs, Lancet; 2018 Feb; Zelenev, Li, et al

HCV Incidence From Injection Paraphernalia , J Infect Dis; 2018 Jan; Heimer, Binka, et al

Must Reads in Hematologic Malignancies

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al

Tyrosine Kinase Inhibitors in Pediatric ALL, Hematology 2017; 2017 Dec 8; Silverman, et al